Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

This study has been completed.
Sponsor:
Collaborator:
AIDS Clinical Trials Group
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00051831
First received: January 16, 2003
Last updated: November 19, 2013
Last verified: November 2013

January 16, 2003
November 19, 2013
October 2003
May 2008   (final data collection date for primary outcome measure)
Frequency of latently infected CD4+ T cells from peripheral blood with replication-competent HIV-1 (in infectious units per million cells) [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00051831 on ClinicalTrials.gov Archive Site
  • Any Grade 3 or 4 adverse experience, including Grade 3 or 4 laboratory value, sign or symptom, and all deaths. [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Targeted events and toxicities will also be considered and these include injection site reactions (any grade), bacterial pneumonia, cellulitis [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • - Level of HIV-1 RNA in plasma as measured by the Roche Ultrasensitive assay [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Level of HIV-1 DNA in PBMC [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Frequency of 2-LTR in PBMC [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • -Sequence of HIV env and HIV pol genes [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • -CD8/CD38 antibody binding capacity (ABC) [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Level of HIV-1 RNA in cerebrospinal fluid [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Level of HIV-1 RNA in genital fluid [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Level of HIV-1 RNA in plasma as measured by an ultra-ultrasensitive assay [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Measures of cell surface density of chemokine (CCR5, CXCR5) receptors [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • - Responses to subject preferences and injection administration concerns questionnaires [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy

HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.

While current HIV treatment with combination antiretroviral therapy (ART) has reduced morbidity and mortality, it does not eradicate or cure HIV infection. A possible explanation for this failure is the persistence of virus in long-lived reservoirs. Resting memory CD4 cells have been proposed as providing a cellular reservoir. Most patients who initiate ART during chronic HIV-1 infection do not experience a detectable reduction in HIV in the latent reservoir; this may be due to low levels of ongoing viral replication that maintains the resting CD4 cell reservoir. Increasing the potency of therapy by inhibiting new viral targets may result in a decrease in the number of latently infected cells and clearance of the latent reservoir. Addition of the fusion inhibitor T-20 to ART including reverse transcriptase inhibitors and protease inhibitors (PIs) may help achieve this goal. This study will evaluate whether treatment naive, chronically infected HIV patients treated with T-20 plus emtricitabine (FTC), ritonavir (RTV), saquinavir (SQV), and tenofovir disoproxil fumarate (TDF) have a measurable decline in the latently infected CD4 cell reservoir. Patients and their physicians may choose different PIs than RTV and SQV, but they will not be provided by the study.

Patients in this study will receive injections of T-20 twice daily in addition to oral FTC and TDF once daily and oral RTV and SQV twice daily. At Week 24, patients will have their latent cell reservoir sampled. Patients whose HIV viral loads are less than 50 copies/ml at or after Week 24 but prior to Week 48 will continue the treatment regimen through the end of the study; their latent cell reservoirs will be tested at Weeks 48, 72, and 96. Patients whose viral loads are between 50 copies/ml and 200 copies/ml will continue the treatment regimen and latent cell sampling, but their regimens may be intensified as determined by the study team. Patients whose viral loads are 200 copies/ml or greater after Week 24 may continue their study regimens, but will no longer contribute latent cell samples.

This study will last 96 weeks. During the first 4 months of the study, patients will have 7 study visits; after that, study visits will be every 8 weeks until the end of the study. Medical history, clinical assessments, and blood collection will occur at every study visit. Pill and ENF vial counts will be assessed, and patients will be asked to complete a medication adherence questionnaire at selected study visits.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Emtricitabine
    Will be administered as one 200-mg capsule orally daily
    Other Names:
    • FTC
    • Emtriva
  • Drug: Enfuvirtide
    Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
    Other Names:
    • ENF
    • Fuzeon
    • T-20
  • Drug: Ritonavir
    Will be administered as one 100-mg capsule orally twice daily
    Other Names:
    • RTV
    • Norvir
  • Drug: Saquinavir
    Will be administered as five hard gel capsules orally twice daily
    Other Names:
    • Invirase
    • Saquinavir mesylate
  • Drug: Tenofovir disoproxil fumarate
    Will be administered as one 300-mg tablet orally daily
    Other Names:
    • TDF
    • Viread
Experimental: 1
Interventions:
  • Drug: Emtricitabine
  • Drug: Enfuvirtide
  • Drug: Ritonavir
  • Drug: Saquinavir
  • Drug: Tenofovir disoproxil fumarate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria

  • HIV-1 infected
  • Viral load of 1,000 copies/ml or greater within 60 days prior to study entry
  • CD4 count of 100 cells/mm3 or greater within 60 days prior to study entry
  • Willing to use acceptable methods of contraception

Exclusion Criteria

  • Previous treatment with any nucleoside analogue, nonnucleoside reverse transcriptase inhibitor, or fusion inhibitor for longer than 7 days
  • Any previous treatment with T-20, lamivudine, or FTC
  • HIV-related vaccine within 6 months prior to study entry
  • Evidence of HIV seroconversion within 6 months prior to study entry
  • Acute AIDS-defining opportunistic infection (OI). Patients who are not clinically stable or who have not been on therapy for the OI for at least 30 days prior to study entry are excluded. Patients who have no evidence of active disease and have been receiving maintenance therapy for AIDS-related OI for at least 30 days are not excluded.
  • Systemic chemotherapy within 30 days of study entry or anticipated need for systemic chemotherapy before the end of the study
  • Treatment with immune modulators such as systemic steroids, IL-2, alpha interferon, G-CSF, erythropoietin, or any investigational agent within 30 days of study entry
  • Allergy to study drugs or their formulations
  • Serious illness, substance abuse, or other medical condition that would compromise the patient's ability to participate in the study
  • Certain primary resistance HIV mutations
  • Pregnancy or breastfeeding
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00051831
A5173, 10006, ACTG A5173
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
AIDS Clinical Trials Group
Study Chair: Joseph J. Eron, Jr., MD University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP